Oak Ridge Investments LLC trimmed its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,205 shares of the biotechnology company’s stock after selling 862 shares during […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) has earned a consensus rating of “Hold” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price objective upped by Stifel Nicolaus from $80.00 to $84.00 in a report issued on Tuesday morning, The Fly reports. Several other brokerages have also issued reports on BPMC. SVB Leerink cut their target price on shares of Blueprint Medicines from $45.00 to $38.00 and set a […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price objective increased by Stifel Nicolaus from $80.00 to $84.00 in a research report sent to investors on Tuesday, The Fly reports. A number of other research analysts have also commented on BPMC. SVB Leerink decreased their price target on shares of Blueprint Medicines from $45.00 to […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its target price upped by Stifel Nicolaus from $80.00 to $84.00 in a research report released on Tuesday morning, The Fly reports. Several other analysts have also issued reports on the stock. Morgan Stanley reduced their target price on shares of Blueprint Medicines from $75.00 to $50.00 and […]